Aprea Therapeutics, Inc. — Director's Dealing 2022

May 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2022-05-18

Reporting Person: SCHADE CHRISTIAN S (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-18	Common Stock	P	37500	$0.6433	Acquired	292616	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1000	Indirect
Common Stock	1000	Indirect
Common Stock	1000	Indirect
Common Stock	1000	Indirect
Common Stock	1000	Indirect
Common Stock	1000	Indirect
Common Stock	5000	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.